5AM Venture Management LLC Invests $19.15 Million in Zentalis Pharmaceuticals, Inc. $ZNTL

5AM Venture Management LLC bought a new position in shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report) in the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor bought 3,947,913 shares of the company's stock, valued at approximately $19,147,378. Zentalis Pharmaceuticals accounts for approximately 0.0% of 5AM Venture Management LLC's holdings, making the stock its 8th biggest position. 5AM Venture Management LLC owned approximately 5.51% of Zentalis Pharmaceuticals as of its most recent SEC filing.

Several other large investors have also made changes to their positions in the business. CTC Alternative Strategies Ltd. acquired a new position in shares of Zentalis Pharmaceuticals during the 1st quarter worth approximately $29,000. The Manufacturers Life Insurance Company acquired a new position in shares of Zentalis Pharmaceuticals during the 2nd quarter worth approximately $69,000. Invesco Ltd. raised its stake in shares of Zentalis Pharmaceuticals by 8.6% during the 4th quarter. Invesco Ltd. now owns 188,582 shares of the company's stock worth $255,000 after buying an additional 14,961 shares during the period. Barr E S & Co. raised its stake in shares of Zentalis Pharmaceuticals by 43.8% during the 4th quarter. Barr E S & Co. now owns 57,500 shares of the company's stock worth $78,000 after buying an additional 17,500 shares during the period. Finally, State of Wyoming acquired a new position in shares of Zentalis Pharmaceuticals during the 2nd quarter worth approximately $91,000.

Zentalis Pharmaceuticals Stock Performance

Shares of ZNTL opened at $3.80 on Friday. Zentalis Pharmaceuticals, Inc. has a one year low of $1.21 and a one year high of $6.95. The stock has a market capitalization of $272.35 million, a price-to-earnings ratio of -1.95 and a beta of 1.92. The stock has a 50 day moving average price of $4.37 and a 200 day moving average price of $3.72.

Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.59) EPS for the quarter, missing the consensus estimate of ($0.49) by ($0.10). On average, analysts predict that Zentalis Pharmaceuticals, Inc. will post -2.14 earnings per share for the current year.

Wall Street Analyst Weigh In

ZNTL has been the subject of several research analyst reports. Rodman & Renshaw assumed coverage on Zentalis Pharmaceuticals in a research note on Thursday, July 23rd. They set a "buy" rating and a $11.00 target price for the company. Wall Street Zen cut Zentalis Pharmaceuticals from a "sell" rating to a "strong sell" rating in a research report on Saturday, August 8th. Mizuho assumed coverage on Zentalis Pharmaceuticals in a research report on Friday, July 17th. They set an "outperform" rating and a $8.00 price target for the company. Weiss Ratings reiterated a "sell (d-)" rating on shares of Zentalis Pharmaceuticals in a research report on Monday, July 6th. Finally, HC Wainwright reiterated a "buy" rating and set a $10.00 price target on shares of Zentalis Pharmaceuticals in a research report on Friday, May 22nd. Four equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus price target of $6.75.

Insider Transactions at Zentalis Pharmaceuticals

In related news, major shareholder Group Walters bought 4,335,000 shares of the company's stock in a transaction on Friday, August 14th. The stock was bought at an average cost of $3.50 per share, for a total transaction of $15,172,500.00. Following the acquisition, the insider directly owned 17,844,973 shares in the company, valued at $62,457,405.50. This represents a 32.09% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 3.80% of the stock is currently owned by insiders.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for oncology. Leveraging a proprietary structure-based drug discovery platform, the company designs selective inhibitors aimed at critical cancer targets. Zentalis' research and development efforts center on delivering differentiated therapies that address unmet medical needs in solid tumors and hematologic malignancies.

The company's lead product candidate, ZN-c3, is an orally administered inhibitor of the p53-MDM2 interaction, currently being evaluated in Phase I clinical trials for advanced solid tumors and hematologic cancers.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source